NCT00440973View on ClinicalTrials.gov

Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

November 30, 2007

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Bevacizumab

monoclonal antibody with anti-angiogenesis properties used as chemotherapy

DRUG

Interleukin-2

immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T \& B lymphocyte proliferation

Trial Locations (1)

77030

Baylor College of Medicine - Methodist Hospital, Houston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

The Methodist Hospital Research Institute

OTHER